Reports
Sale
Global Pulmonary Drug Delivery Systems Market Size, Report: By Product Type: Dry Powder Inhalers Metered Dose Inhalers, Nebulizers, Others; By Applications: Cystic Fibrosis, Asthma, Allergic Rhinitis, COPD, Others; By End User: Hospitals, Diagnostic Centres, Homecare Settings, Others; Regional Analysis; Competitive Landscape; 2024-2032
Global Pulmonary Drug Delivery Systems Market Outlook
The global pulmonary drug delivery systems market size was valued at USD 56.9 billion in 2023, driven by the increasing incidence of respiratory conditions across the globe. The market size is anticipated to grow at a CAGR of 5.65% during the forecast period of 2024-2032 to achieve a value of USD 93.3 billion by 2032.
Pulmonary Drug Delivery Systems: Introduction
Pulmonary drug delivery systems are medical devices or drug formulations designed to deliver medications directly to the lungs through inhalation. These systems are used to treat various respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory infections, among others. Pulmonary drug delivery offers several advantages, including rapid onset of action, targeted drug delivery to the lungs, and reduced systemic side effects compared to oral or intravenous administration.
Global Pulmonary Drug Delivery Systems Market Analysis
The growth of the market is driven by the strategic collaborations between pharma giants to resolve issues together resulting in increased market growth. For example, the strategic partnership between Hovione and H&T Presspart to develop the Sunriser© Capsule-based DPI platform is expected to address the evolving requirements of the pulmonary drug delivery systems market as they offer more efficient and adaptable solutions for inhalable medications. The development of the Sunriser© DPI is expected to result in more efficient and effective delivery of inhalable drugs resulting in enhanced patient compliance and outcomes for various respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD).
The market growth is also driven by increased innovation, coupled with expanded product offerings, and improved drug delivery options for patients. Such collaborations are expected to influence the market greatly as they may result in patient-friendly, efficient, and adaptable inhalation solutions propelling the global pulmonary drug delivery systems market growth.
Global Pulmonary Drug Delivery Systems Market Segmentations
Market Breakup by Product Type
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
- Jet Nebulizers
- Soft Mist Nebulizers
- Ultrasonic Nebulizers
- Others
Market Breakup by Applications
- Cystic Fibrosis
- Asthma
- Allergic Rhinitis
- COPD
- Others
Market by End User
- Hospitals
- Diagnostic Centres
- Homecare Settings
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Pulmonary Drug Delivery Systems Market Overview
The global market for pulmonary drug delivery systems is experiencing significant growth driven by the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. With these conditions continuing to affect a substantial portion of the global population, there is a growing demand for effective drug delivery systems specifically designed for pulmonary treatments in the market.
Additionally, advancements in inhalation technologies and drug formulations are also enhancing the efficiency and effectiveness of pulmonary drug delivery, further propelling the pulmonary drug delivery systems market growth.
Furthermore, the COVID-19 pandemic has highlighted the importance of respiratory health, leading to increased awareness and investments in pulmonary drug delivery systems. The need for efficient administration of respiratory medications, including vaccines and therapies for various lung infections is expected to further drive innovation and development of novel delivery devices in the market, propelling the market growth.
The increasing geriatric population, particularly in developed countries, is contributing to increased respiratory-related illnesses, further aiding the pulmonary drug delivery systems market demand. As healthcare systems focus on patient-centric care and improved treatment outcomes, the market is witnessing a surge in research and development activities, new product launches, and strategic collaborations. All these factors collectively are boosting the global market and are expected to drive the market in coming years as well.
Global Pulmonary Drug Delivery Systems Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Koninklijke Philips NV
- GlaxoSmithKline PLC
- 3M
- Novartis AG
- Boehringer Ingelheim International GmbH
- AstraZeneca
- Cipla Inc.
- Merck & Co.
- GF Health Products Inc.
- Aerogen
- PARI GmbH
- Gilbert Technologies
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Pulmonary Drug Delivery Systems Market Overview
3.1 Global Pulmonary Drug Delivery Systems Market Historical Value (2017-2023)
3.2 Global Pulmonary Drug Delivery Systems Market Forecast Value (2024-2032)
4 Global Pulmonary Drug Delivery Systems Market Landscape
4.1 Global Pulmonary Drug Delivery Systems Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Pulmonary Drug Delivery Systems Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
5 Global Pulmonary Drug Delivery Systems Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Pulmonary Drug Delivery Systems Market Segmentation
6.1 Global Pulmonary Drug Delivery Systems Market by Product Type
6.1.1 Market Overview
6.1.2 Dry Powder Inhalers
6.1.3 Metered Dose Inhalers
6.1.4 Nebulizers
6.1.4.1 Jet Nebulizers
6.1.4.2 Soft Mist Nebulizers
6.1.4.3 Ultrasonic Nebulizers
6.1.5 Others
6.2 Global Pulmonary Drug Delivery Systems Market by Applications
6.2.1 Market Overview
6.2.2 Cystic Fibrosis
6.2.3 Asthma
6.2.4 Allergic Rhinitis
6.2.5 COPD
6.2.6 Others
6.3 Global Pulmonary Drug Delivery Systems Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Diagnostic Centres
6.3.4 Homecare Settings
6.3.5 Others
6.4 Global Pulmonary Drug Delivery Systems Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Pulmonary Drug Delivery Systems Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Pulmonary Drug Delivery Systems Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Pulmonary Drug Delivery Systems Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Pulmonary Drug Delivery Systems Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Pulmonary Drug Delivery Systems Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Koninklijke Philips NV
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 GlaxoSmithKline PLC
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 3M
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Novartis AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Boehringer Ingelheim International GmbH
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 AstraZeneca
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Cipla Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Merck & Co.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 GF Health Products Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Aerogen
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 PARI GmbH
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Gilbert Technologies
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
18 Global Pulmonary Drug Delivery Systems Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 56.9 billion in 2023, driven by increased awareness.
The market is anticipated to grow at a CAGR of 5.65% during the forecast period of 2024-2032 and is likely to reach a market value of USD 93.3 billion by 2032.
The increasing prevalence of respiratory diseases is a major factor driving the market growth.
The market growth is driven by trends such as strategic collaborations between pharma giants to develop patient-centric solutions.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Various products in the market include dry powder inhalers, metered dose inhalers, and nebulizers, among others.
They find wide applications in cystic fibrosis, asthma, allergic rhinitis, and COPD, among others.
End users in the market are hospitals, diagnostic centres, and home care settings, among others.
Key players involved in the market are Koninklijke Philips NV, GlaxoSmithKline PLC, 3M, Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca, Cipla Inc., Merck & Co., GF Health Products Inc., Aerogen, PARI GmbH, and Gilbert Technologies.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER